COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03926988
Recruitment Status : Recruiting
First Posted : April 25, 2019
Last Update Posted : January 22, 2020
Information provided by (Responsible Party):

Brief Summary:
A prospective, open label, 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Device: NeVa Stent Retriever Not Applicable

Detailed Description:
This is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 400 subjects at up 20 sites will participate in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-Label, Multi-Center, Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
NeVa Stent Retriever
Device: NeVa Stent Retriever
mechanical neurothrombectomy

Primary Outcome Measures :
  1. Recanalization rate of occluded target vessel [ Time Frame: post-procedure day 0 ]
    Recanalization rate of occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: Only subjects already treated with the NeVa devices can be considered for enrollment.

  1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:

    1.1. Subject has failed IV t-PA therapy

    1.2. Subject is contraindicated for IV t-PA administration

  2. Age ≥18
  3. NIHSS score ≥ 6
  4. Pre-stroke mRS score of ≤ 1
  5. Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
  6. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW])
  7. Imaging Inclusion Criteria:

    7.1. Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 if treatment started 0-6 hours from TLKW ASPECTS 8-10 if treatment started 6-24 hours from TLKW

    7.2. CT Perfusion core ≤50 cc

    7.3. MRI DWI core ≤50 cc

  8. Subject or legal representative is able and willing to give informed consent within 48 hours after the intervention.

Exclusion Criteria:

  1. Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
  2. Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration.
  3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
  4. Cerebral vasculitis
  5. History of severe allergy to contrast medium.
  6. Known allergy to NeVa materials (nitinol, stainless steel)
  7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
  8. Systemic infection
  9. Significant mass effect with midline shift
  10. Evidence of intracranial tumor (except small meningioma)
  11. Inability to deploy NeVA device for at least one pass for any other reason
  12. Life expectancy less than 6 months
  13. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03926988

Layout table for location contacts
Contact: Kathleen Calderon 615-206-7788

Layout table for location information
Vall d'Hebron Recruiting
Barcelona, Spain
Contact: Marc Ribo, MD    932746000 ext 6326   
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Vesalio Identifier: NCT03926988    
Other Study ID Numbers: VS-005 / D
First Posted: April 25, 2019    Key Record Dates
Last Update Posted: January 22, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases